Sanofi rode the growing sales wave for blockbuster immunology drug Dupixent (dupilumab) in Q2 but reported lower-than-expected profits after outlaying money to develop new treatments. Dupixent ...

Discover high-conviction stock picks and new investing opportunities with the TipRanks Smart Investor Newsletter The RAPID registry from Regeneron and Sanofi tracks how real patients with asthma start ...

Sanofi’s SNY stock has declined 5.9% in the past three months despite reporting double-digit sales and earnings growth in the ...

Sanofi SNY and partner Regeneron REGN announced that the FDA has approved their blockbuster drug, Dupixent, for its sixth indication — chronic obstructive pulmonary disease (COPD) — in the United ...

Why Sanofi’s recent news flow matters for shareholders Sanofi (ENXTPA:SAN) has packed several key updates into late April, from appointing Belén Garijo as Chief Executive Officer and refreshing its ...

The LIBERTY-CUPID C study enrolled CSU patients aged six years and older who remained symptomatic despite standard-of-care (SOC) antihistamines and were not previously treated with Novartis ...

Sanofi and Regeneron Pharmaceuticals drug Dupixent has won FDA approval for chronic spontaneous urticaria, introducing a new approach to the treatment of this inflammatory skin disorder. It’s the ...

July 25 (Reuters) - Sanofi (SASY.PA), opens new tab on Thursday raised its full-year profit outlook after strong demand for blockbuster asthma drug Dupixent and better-than-expected sales of new ...

(Reuters) -Sanofi and partner Regeneron Pharmaceuticals have secured the European regulator's backing for use of Dupixent in patients with a chronic lung disease even as the U.S. Food and Drug ...

Sept 27 (Reuters) - The U.S. Food and Drug Administration has approved Sanofi (SASY.PA), opens new tab and Regeneron's (REGN.O), opens new tab blockbuster drug Dupixent for patients with a chronic ...